0001093557-21-000177.txt : 20210708 0001093557-21-000177.hdr.sgml : 20210708 20210708194551 ACCESSION NUMBER: 0001093557-21-000177 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210706 FILED AS OF DATE: 20210708 DATE AS OF CHANGE: 20210708 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Balo Andrew K CENTRAL INDEX KEY: 0001323190 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51222 FILM NUMBER: 211081374 MAIL ADDRESS: STREET 1: C/O DEXCOM, INC. STREET 2: 5555 OBERLIN DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: DEXCOM INC CENTRAL INDEX KEY: 0001093557 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 330857544 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582000200 MAIL ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2021-07-06 0 0001093557 DEXCOM INC DXCM 0001323190 Balo Andrew K 6340 SEQUENCE DRIVE SAN DIEGO CA 92121 0 1 0 0 * Common Stock 2021-07-06 4 S 0 578 428.5056 D 15805 I by Trust Common Stock 2021-07-06 4 S 0 400 429.331 D 15405 I by Trust Common Stock 2021-07-06 4 S 0 1710 430.5576 D 13695 I by Trust Common Stock 2021-07-06 4 S 0 286 432.0479 D 13409 I by Trust Common Stock 16533 D On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. This transaction was executed in multiple trades at prices ranging from $428.125 to $429.060. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. This transaction was executed in multiple trades at prices ranging from $429.141 to $429.401. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. This transaction was executed in multiple trades at prices ranging from $430.270 to $430.919. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. This transaction was executed in multiple trades at prices ranging from $431.455 to $432.050. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. *EVP Regulatory Strategy Clinical Affairs and Strategic Partnership Development By: Jereme Sylvain For: Andrew K Balo 2021-07-08